181 related articles for article (PubMed ID: 15695797)
21. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
[TBL] [Abstract][Full Text] [Related]
23. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.
Tóth K; Vaughan MM; Peress NS; Slocum HK; Rustum YM
Am J Pathol; 1996 Sep; 149(3):853-8. PubMed ID: 8780389
[TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Findling-Kagan S; Sivan H; Ostrovsky O; Nagler A; Galski H
Leuk Res; 2005 Apr; 29(4):407-14. PubMed ID: 15725475
[TBL] [Abstract][Full Text] [Related]
25. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo.
Hoffend J; Mier W; Schuhmacher J; Schmidt K; Dimitrakopoulou-Strauss A; Strauss LG; Eisenhut M; Kinscherf R; Haberkorn U
Nucl Med Biol; 2005 Apr; 32(3):287-92. PubMed ID: 15820764
[TBL] [Abstract][Full Text] [Related]
26. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
[TBL] [Abstract][Full Text] [Related]
28. Preparation, biodistribution, and small animal PET of 45Ti-transferrin.
Vavere AL; Welch MJ
J Nucl Med; 2005 Apr; 46(4):683-90. PubMed ID: 15809492
[TBL] [Abstract][Full Text] [Related]
29. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
30. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Gangloff A; Hsueh WA; Kesner AL; Kiesewetter DO; Pio BS; Pegram MD; Beryt M; Townsend A; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Nov; 46(11):1866-71. PubMed ID: 16269601
[TBL] [Abstract][Full Text] [Related]
31. In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Achten E; Dierckx RA; Mertens J; Slegers G
J Nucl Med; 2005 Mar; 46(3):532-9. PubMed ID: 15750170
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?
Kostakoglu L
Clin Lymphoma; 2002 Mar; 2(4):242-8. PubMed ID: 11970764
[TBL] [Abstract][Full Text] [Related]
33. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.
van der Sandt IC; Smolders R; Nabulsi L; Zuideveld KP; de Boer AG; Breimer DD
Eur J Pharm Sci; 2001 Aug; 14(1):81-6. PubMed ID: 11457654
[TBL] [Abstract][Full Text] [Related]
34. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
[TBL] [Abstract][Full Text] [Related]
35. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine.
Pichler A; Prior JL; Piwnica-Worms D
Proc Natl Acad Sci U S A; 2004 Feb; 101(6):1702-7. PubMed ID: 14755051
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo characterization of 67Ga(3+) complexes with cis,cis-1,3,5-triamino-cyclohexane-N,N',N"-triacetic acid derivatives.
Dadachova E; Park C; Eberly N; Ma D; Paik CH; Brechbiel MW
Nucl Med Biol; 2001 Aug; 28(6):695-701. PubMed ID: 11518651
[TBL] [Abstract][Full Text] [Related]
37. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
[TBL] [Abstract][Full Text] [Related]
38. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo.
Brinkmann U
Novartis Found Symp; 2002; 243():207-10; discussion 210-2, 231-5. PubMed ID: 11990778
[TBL] [Abstract][Full Text] [Related]
39. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
[TBL] [Abstract][Full Text] [Related]
40. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
Cordon-Cardo C; O'Brien JP; Boccia J; Casals D; Bertino JR; Melamed MR
J Histochem Cytochem; 1990 Sep; 38(9):1277-87. PubMed ID: 1974900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
